The American Journal of Infection Control is a leading peer-reviewed publication dedicated to advancing the field of infection prevention and control. Published by Mosby-Elsevier, this journal has been a crucial resource since its inception in 1980, focusing on the intersection of infectious diseases, public health, and health policy. As of 2023, it holds an impressive Q1 ranking in both Health Policy and Public Health, Environmental and Occupational Health, while also achieving Q2 rankings in Epidemiology and Infectious Diseases. With an increasing impact factor and a strong reputation reflected in its Scopus rankings, the journal appeals to researchers, health professionals, and students committed to preventing the spread of infections and enhancing healthcare safety. Although it does not currently offer Open Access, the journal ensures broad dissemination of its vital research through various subscription options. By fostering interdisciplinary collaboration and evidence-based practices, the American Journal of Infection Control plays a pivotal role in shaping effective infection control policies and practices worldwide.

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, published by Cambridge University Press, is a leading academic journal specializing in the critical fields of epidemiology, infectious diseases, and medical microbiology. With a history of publication dating back to 1988 and an expected continuation through 2024, the journal has established itself as a pivotal resource for researchers, healthcare professionals, and students alike. The journal's impact is reflected in its impressive rankings, positioning it in the second quartile for Epidemiology and the first quartile for both Infectious Diseases and Medical Microbiology as of 2023. This esteemed journal is dedicated to the dissemination of high-quality research that informs best practices in infection control and enhances patient safety across healthcare settings. Although access to its content is not open, the rigorous peer-review process ensures that all published articles contribute significantly to the body of knowledge in these vital areas. With a commitment to bridging the gap between research and practice, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY remains an essential publication for those committed to the advancement of public health and the science of infection prevention.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, published by Elsevier Masson SAS Éditeur, is a distinguished journal dedicated to the field of medicine, specifically focusing on various aspects of medical research and advancements. With its inception dating back to 1947, this journal has served as a vital platform for the dissemination of scholarly articles, reviews, and case studies, contributing significantly to the knowledge base within the medical community. Although it is indexed in the Q4 category for medicine (miscellaneous) and has a Scopus rank of #444/636, the journal maintains a key role in promoting ongoing education and discussion among researchers and professionals. The journal does not currently offer Open Access options, allowing for a traditional subscription model that appeals to institutions and individuals seeking comprehensive resources. With a commitment to addressing contemporary medical dilemmas and fostering innovation, the BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE is an essential resource for scholars and practitioners aiming to stay abreast of the latest developments in the field.

Infection Prevention in Practice is a leading academic journal published by ELSEVIER that has established itself as a vital resource in the domains of Infectious Diseases and Public Health. With its Open Access policy implemented since 2019, the journal enhances global accessibility to cutting-edge research and practical insights aiming to reduce the risk of infections in various settings. It proudly holds a Q3 ranking in Infectious Diseases and a Q2 ranking in Public Health, Environmental and Occupational Health as of 2023, showcasing its impact and relevance within the scientific community—particularly with a Scopus rank placing it in the 71st percentile for public health research. Its scope includes the latest advancements, strategies, and practices in infection prevention, making it an indispensable read for researchers, healthcare professionals, and students dedicated to improving health outcomes and combating infectious diseases effectively. The journal operates from its base in the United Kingdom and reaches a global audience, fostering collaboration and innovation in infection control practices.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.